Aemetis (NASDAQ:AMTX - Get Free Report) is expected to issue its Q1 2025 quarterly earnings data before the market opens on Thursday, May 8th. Analysts expect the company to announce earnings of ($0.39) per share and revenue of $59.35 million for the quarter.
Aemetis Stock Performance
Shares of Aemetis stock traded down $0.01 on Tuesday, hitting $1.27. The company's stock had a trading volume of 123,501 shares, compared to its average volume of 695,996. The company has a market capitalization of $67.45 million, a price-to-earnings ratio of -0.56 and a beta of 1.47. Aemetis has a 1 year low of $1.22 and a 1 year high of $4.73. The firm has a fifty day moving average price of $1.63 and a 200-day moving average price of $2.44.
Analyst Upgrades and Downgrades
Several research analysts have recently weighed in on the company. Ascendiant Capital Markets upped their target price on Aemetis from $18.00 to $19.00 and gave the stock a "buy" rating in a research note on Monday, March 17th. StockNews.com raised shares of Aemetis to a "sell" rating in a research note on Wednesday, February 5th. Finally, HC Wainwright reiterated a "buy" rating and issued a $28.00 price objective on shares of Aemetis in a report on Friday, March 14th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of $14.56.
View Our Latest Stock Analysis on AMTX
Aemetis Company Profile
(
Get Free Report)
Aemetis, Inc operates as a renewable natural gas and renewable fuels company. It operates through three segments: California Ethanol, California Dairy Renewable Natural Gas, and India Biodiesel. The company focuses on the operation, acquisition, development, and commercialization of technologies to produce low and negative carbon intensity renewable fuels that replace fossil-based products.
See Also
Before you consider Aemetis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aemetis wasn't on the list.
While Aemetis currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
